1403. Daptomycin Combined with Low Dose Ceftriaxone Prevents the Emergence of Daptomycin Resistance against Streptococcus mitis-oralis Group in an In vitro Model of Simulated Endocardial Vegetations (SEVs)
Session: Poster Abstract Session: PK/PD Studies
Friday, October 5, 2018
Room: S Poster Hall
Posters
  • s.mitis poster 1-10-18-17.5.pdf (6.7 MB)
  • Background:

    The viridans group streptococci (VGS) are a heterogeneous group of microorganisms that form portion of the normal oral flora of humans. Among the VGS, S. mitis-oralis are the most common cause of infective endocarditis in the developing world, as well as the leading cause of the “toxic Strep syndrome” in neutropenic cancer patients. Therapeutic options are often limited by frequent ß-lactam resistance, as well as vancomycin tolerance. Daptomycin (DAP) has been suggested as an alternative therapeutic option for invasive S. mitis-oralis infections. However, the ability of these strains to rapidly evolve high-level and durable DAP-resistance (DAP-R) is problematic. Recent data have suggested the potential for combined DAP +ß-lactam therapy to circumvent this issue.

    Methods:

    Using human-simulated dosing, the activities of DAP (6, 8,10 or 12 mg/kg/day x 4d) alone vs DAP (6 mg/kg/day) +(CRO) (500 mg daily x 4d or 500 mg, given once on day one) were assessed against two DAP-susceptible (DAP-S) S. mitis-oralis strains (SF100; 351) employing a PK-PD model of simulated endocardial vegetations (SEVs).

    Results:

    DAP alone was not bactericidal at any dose-regimen, and regrowth of high-level DAP-R isolates was observed in both strains (MIC increase from 0.5 to >64 µg/ml). Combinations of DAP +CRO at either dose-regimen yielded significant reductions in log10CFU/g amounts within SEVs for both strains (~ 6 log10 CFU/g and to detection limits) within 24h. In addition, no DAP-R strains were detected in either DAP+ CRO combination regimens over the 96-hour exposure period.

    Conclusion:

    Combinations of DAP+ low-dose CRO (even single dosing) showed promise to forestall the emergence of DAP-R in S. mitis-oralis strains. Such regimens can potentially lead to optimizing treatment outcomes with DAP therapy, with minimal ß-lactam exposures. Further research in relevant in vivo models and clinically is warranted to determine the most optimized DAP+ CRO dose-regimens for the prevention of emergence of DAP-R among S. mitis-oralis strains.

    Razieh Kebriaei, Ph.D., Antiinfective Research Laboratory, Department of Pharmacy Practice, Wayne State University, Eugene Applebaum College of Pharmacy & health Sciences, Detroit, MI, Seth Rice, BSc, Pharmacy Practice, Wayne State University, Detroit, MI, Kyle Stamper, BSc, Wayne State University, Detroit, MI, Cristina Garcia-De-La-Maria, PhD, ID Service Hospital clinic-IDIBAPS, Barcelona, Spain, Nagendra Mishra, PhD, LABiomed Research Institute at Harbor-UCLA Medical Center, Torrance, CA, Jose M Miro, MD, PhD, Hospital Clinic-IDIBAPS, Barcelona, Spain, Cesar Arias, MD, PhD, FIDSA, Microbiology and Molecular Genetics, University of Texas McGovern Medical School, Houston, TX, Truc Tran, PharmD, Internal Medicine, University of Texas McGovern Medical School, Houston, TX, Paul Sullam, MD, Department of Medicine - Infectious Disease, UCSF, san fransisco, CA, Arnold Bayer, MD, FIDSA, Geffen Sch. of Med. at UCLA, Los Angeles, CA and Michael J. Rybak, PharmD, MPH, PhD, 259 Mack Ave, Suit 4131, Eugene Applebaum College of Pharmacy and Health Sciences Bldg, 259 Mack Ave, Detroit, MI

    Disclosures:

    R. Kebriaei, None

    S. Rice, None

    K. Stamper, None

    C. Garcia-De-La-Maria, None

    N. Mishra, None

    J. M. Miro, Abbvie: Consultant and Grant Investigator , Consulting honoraria and Research grant . Bristol-Myers Squibb: Consultant and Grant Investigator , Consulting honoraria and Research grant . Genentech: Consultant and Grant Investigator , Consulting honoraria and Research grant . Medtronic: Consultant and Grant Investigator , Consulting honoraria and Research grant . Novartis: Consultant and Grant Investigator , Consulting honoraria and Research grant . Gilead Sciences: Consultant and Grant Investigator , Consulting honoraria and Research grant . Pfizer: Consultant and Grant Investigator , Consulting honoraria and Research grant . ViiV Healthcare: Consultant and Grant Investigator , Consulting honoraria and Research grant .

    C. Arias, Merck & Co., Inc.: Grant Investigator , Research support . MeMed: Grant Investigator , Research support . Allergan: Grant Investigator , Research support .

    T. Tran, None

    P. Sullam, None

    A. Bayer, Trellis: grant recipient , Grant recipient . Contrafect: grant recipient , Grant recipient . Theravance: grant recipient , Grant recipient .

    M. J. Rybak, Allergan: Consultant , Grant Investigator and Speaker's Bureau , Research grant and Research support . Achaogen: Consultant , Grant Investigator and Speaker's Bureau , Consulting fee , Research grant and Research support . Bayer: Consultant , Grant Investigator and Speaker's Bureau , Consulting fee , Research grant and Research support . Melinta: Consultant , Grant Investigator and Speaker's Bureau , Consulting fee , Research grant and Research support . Merck: Consultant , Grant Investigator and Speaker's Bureau , Consulting fee , Research grant and Research support . Theravance: Consultant , Grant Investigator and Speaker's Bureau , Consulting fee , Research grant and Research support . Sunovian: Consultant , Grant Investigator and Speaker's Bureau , Consulting fee , Research grant and Research support . Zavante: Consultant , Grant Investigator and Speaker's Bureau , Consulting fee , Research grant and Research support . NIAID: Consultant , Grant Investigator and Speaker's Bureau , Consulting fee , Research grant and Research support .

    See more of: PK/PD Studies
    See more of: Poster Abstract Session

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.